Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
68.9 USD -0.09% Intraday chart for Axonics, Inc. +0.22% +10.72%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Axonics Wins Shareholder Approval of Merger With Boston Scientific MT
Axonics to File for Review After Patent Board Invalidates Claims in Medtronic Case MT
Medtronic to Ask Court to Resume Patent Infringement Case Against Axonics After Favorable Patent Office Ruling MT
Axonics to Sell Rechargeable Sacral Neuromodulation System in Europe Starting April MT
North American Morning Briefing : Stock Futures -2- DJ
Axonics Q4 Earnings, Revenue Rise -- Shares Edge Higher After Hours MT
Axonics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (AXNX) AXONICS Posts Q4 Revenue $109.7M MT
Boston Scientific Prices $2.17 Billion Euro-Denominated Notes Offering MT
Axonics Insider Sold Shares Worth $2,381,662, According to a Recent SEC Filing MT
Axonics Insider Sold Shares Worth $1,125,432, According to a Recent SEC Filing MT
North American Morning Briefing : TSMC Results -2- DJ
Needham Downgrades Axonics to Hold From Buy MT
North American Morning Briefing : Central Bankers -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Truist Securities Downgrades Axonics to Hold From Buy, Adjusts Price Target to $71 From $73 MT
CL King Downgrades Axonics to Neutral From Buy MT
Leerink Partners Downgrades Axonics to Market Perform From Outperform, Sets Price Target at $71 MT
Piper Sandler Downgrades Axonics to Neutral From Overweight, Cuts Price Target to $71 From $75 MT
Axonics Insider Sold Shares Worth $1,103,961, According to a Recent SEC Filing MT
North American Morning Briefing : Focus Fixed on -2- DJ
Wells Fargo Downgrades Axonics to Equalweight From Overweight, Raises Price Target to $71 From $68 MT
Nephron Research Downgrades Axonics to Hold From Buy, Raises Price Target to $71 From $65 MT
Wolfe Research Downgrades Axonics to Peer Perform From Outperform MT
RBC Lifts Price Target on Boston Scientific to $67 From $61, Cites Stock Runup, Growth Opportunities Amid Axonics Deal, Outperform Kept MT
Chart Axonics, Inc.
More charts
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat bladder and bowel dysfunction. It has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10 cubic centimeters (cc) in volume, utilizes constant current stimulation, a recharge-free patient remote control and offers broad magnetic resonance imaging (MRI) access. Its SNM systems include an easy-to-use wireless patient remote control that does not require recharging or replacement batteries. It also offers a clinician programmer that guides the implanting physician through lead placement and stimulation programming.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
68.9 USD
Average target price
71.8 USD
Spread / Average Target
+4.21%
Consensus
  1. Stock
  2. Equities
  3. Stock Axonics, Inc. - Nasdaq
  4. News Axonics, Inc.
  5. Axonics Q3 Loss Shrinks as Revenue Advances; Company Boosts 2022 Revenue Guidance